YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Champions LS apps MDS


March 7, 2002

MDS Proteomics Inc.
Frank Gleeson
President and CEO

The Future Is In Silico Design

What is the history of your organization’s involvement in life sciences?
Gleeson
: Established in 1999, MDS Proteomics is a pioneer in the field of proteomic-enabled drug discovery. MDS Proteomics’ goal is to transform the productivity of the pharmaceutical industry in discovering and developing new medicines for the treatment of disease.

What is your vision for the development of the life sciences market?
Gleeson
: I am personally exhilarated by the prospect of assembling new technologies to radically transform the drug discovery and development process for the benefit of people. We are at a momentous time in medical history. By understanding disease at the molecular level, the future will see much more disease specific therapeutic treatments that are not only more effective but also have fewer untoward side effects. The sequencing of the human genome has taught us how to fuse together new analytical technologies, advances in basic biology, and breakthroughs in high-performance supercomputing to conduct research on a very large scale.

What organizational assets have you developed to serve this community?
Gleeson
: The company has developed proprietary capabilities in large-scale proteomic systems, including ultra-sensitive analytical technology for studying proteins; high-performance supercomputing for interpreting the vast amounts of data generated by proteomics (proteomic generates approximately 1,000 times more information than genomics); high-throughput, roboticized molecular biology; in silico drug design and screening; and novel approaches to directly studying protein function and cellular regulation for the purpose of designing new therapeutics.

What products and services does your company provide to the life sciences market?
Gleeson
: MDS Proteomics provides a range of collaborative research capabilities designed to improve the productivity of the biopharmaceutical industry for the discovery and development of new medicines.

There are seven principal ways MDS Proteomics assists partners:

1. Functional annotation of disease relevant genes (i.e., what protein[s] does the gene make and how are they involved in disease).
2. Mapping of protein pathways associated with proteins implicated in disease to determine where to intervene in a disease pathway.
3. Large-scale analysis of the phosphorylation profiles of proteins in cells and human tissue in response to disease and to drug treatment.
4. The discovery of membrane-bound antigen proteins as prospective targets for antibody therapeutics.
5. Determination of the mechanism of action of drug candidates by identifying the protein targets for drugs and the protein pathways that they affect.
6. Identification of protein biomarkers of disease from bodily fluids and serum to diagnose and monitor disease progression and patient response to drugs.
7. MDS Proteomics is able to design small-molecule drug candidates and to screen millions of potential compounds in silico.
www.mdsp.com

Return to main index page.


Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.